reported that CD19-targeted chimeric antigen receptor (CAR) T-cell therapy was successful in refractory SLE, and the rapid disappearance of dsDNA autoantibodies during CD19 CAR-T cell therapy suggested CD19-targeted plasmablasts as the major source of these antibodies (53). The gene discussed is CD19; the disease is systemic lupus erythematosus.